# InflaRx (IFRX) — News

IFRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ifrx/news

## Recent headlines

- [Inflarx NV: Needham initiates coverage with buy rating; target price $8](https://www.ainvest.com/news/inflarx-nv-needham-initiates-coverage-buy-rating-target-price-8-2609) — AInvest Wire, Sep 14, 2026
  Needham & Company has initiated coverage of InflaRx N.V. (NASDAQ: IFRX) with a "Buy" rating and a target price of $8 per share, reflecting growing confidence in the company’s therapeutic pipeline and strategic direction. InflaRx, a clinical-stage biopharmaceutical firm, is developing vilobelimab, a…
- [Inflarx NV - May offer up to $250 mln in securities - SEC filing](https://www.ainvest.com/news/inflarx-nv-offer-250-mln-securities-sec-filing-2608) — AInvest Wire, Aug 6, 2026
- [Inflarx NV - to engage with EMA on Vilocibimab and Izicopan for AAV approval](https://www.ainvest.com/news/inflarx-nv-engage-ema-vilocibimab-izicopan-aav-approval-2606) — AInvest Wire, Jun 30, 2026
  InflaRx N.V. (Nasdaq: IFRX) is advancing its development programs for both vilobelimab and izicopan, with a focus on engaging regulatory authorities to support potential approvals in key indications. The company has outlined plans to interact with the European Medicines Agency (EMA) regarding…
- [Inflarx assessing feasibility of strategy for AAV in Europe](https://www.ainvest.com/news/inflarx-assessing-feasibility-strategy-aav-europe-2606) — AInvest Wire, Jun 30, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).